伏索利肽
伏索利肽是一种用于治疗软骨发育不全症的药物。[1]伏索利肽由拜玛林制药研发。 [1][2][3][4]
有患者在注射伏索利肽后注射部位会肿胀、瘙痒、发红或疼痛，还有患者会呕吐和血压下降。这些都是常见的副作用 [1]
2021年8月，伏索利肽在欧盟国家获批上市[1][5][2] ，并于2021年11月在美国获批上市 [6]。伏索利肽在美国和欧盟具有孤儿药地位。 [1][2][3][4]
参考文献
[编辑]- ^ 1.0 1.1 1.2 1.3 1.4 Voxzogo EPAR. European Medicines Agency. 23 June 2021 [9 September 2021]. （原始内容存档于10 September 2021）.
- ^ 2.0 2.1 2.2 European Commission Approves BioMarin's Voxzogo (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close (新闻稿). BioMarin Pharmaceutical. 27 August 2021 [9 September 2021]. （原始内容存档于28 August 2021）.
- ^ 3.0 3.1 Food and Drug Administration Accepts BioMarin's New Drug Application for Vosoritide to Treat Children with Achondroplasia (新闻稿). BioMarin Pharmaceutical. 2 November 2020 [9 September 2021]. （原始内容存档于10 September 2021）.
- ^ 4.0 4.1 Advancing Health Through Innovation: New Drug Therapy Approvals 2021. U.S. Food and Drug Administration (FDA) (报告). 13 May 2022 [22 January 2023]. （原始内容 (PDF)存档于6 December 2022）.
- ^ Voxzogo Product information. Union Register of medicinal products. [3 March 2023]. （原始内容存档于4 March 2023）.
- ^ BioMarin Receives FDA Approval for Voxzogo (vosoritide) for Injection, Indicated to Increase Linear Growth in Children with Achondroplasia Aged 5 and Up with Open Growth Plates (新闻稿). BioMarin Pharmaceutical. 19 November 2021 [19 November 2021]. （原始内容存档于6 August 2022）.